Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | PTGIR | P43119 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28455980 | 0.95 | SMN1; SMN2 (0.90) | SMN1; SMN2TSHRSIGMAR1HIF1AEPAS1 | |
| SCHEMBL28577542 | 0.92 | SMN1; SMN2 (0.85) | SMN1; SMN2TSHRSIGMAR1HIF1AEPAS1 | |
| SCHEMBL28583600 | 0.88 | SMN1; SMN2 (0.77) | SMN1; SMN2TSHRSIGMAR1HIF1AEPAS1 | |
| SCHEMBL26098259 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2TSHRSIGMAR1HIF1AEPAS1 | |
| SCHEMBL19285228 | 0.87 | SIGMAR1 (0.85) | SMN1; SMN2SIGMAR1PTGIRALDH1A1 | |
| SCHEMBL1043952 | 0.87 | SIGMAR1 (0.85) | SMN1; SMN2SIGMAR1PTGIRALDH1A1 | |
| SCHEMBL20804352 | 0.87 | SIGMAR1 (0.85) | SMN1; SMN2SIGMAR1PTGIRALDH1A1 | |
| SCHEMBL15467001 | 0.84 | HRH3 (0.87) | SMN1; SMN2HIF1AEPAS1HRH3MAPT | |
| SCHEMBL5591894 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2TSHRSIGMAR1HIF1AEPAS1 | |
| SCHEMBL3171551 | 0.83 | PTGIR (0.81) | SMN1; SMN2TSHRSIGMAR1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | claimed |
| CN-109415345-A | Broad spectrum influenza inhibitor based on pyridazinone | 豪夫迈·罗氏有限公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | disclosed |
| CN-105367576-A | Pyrrolopyrimidine compounds as TLR7 agonists | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2016-03-02 | — | — | CN | disclosed |
| US-20150301461-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, ELECTROPHOTOGRAPHIC APPARATUS AND PHTHALOCYANINE CRYSTAL | CANON KABUSHIKI KAISHA (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150301461-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, ELECTROPHOTOGRAPHIC APPARATUS AND PHTHALOCYANINE CRYSTAL | CANON KABUSHIKI KAISHA (JP) | 2015-10-22 | — | — | US | disclosed |
| CN-101765585-A | Antibacterial agent | ACHAOGEN INC | 2010-06-30 | — | — | CN | disclosed |
| EP-0915856-A4 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | disclosed |
| US-6271249-B1 | Diphenyl imidazoles as potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6077861-A | MODULATORS OF THE LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM (BK) CHANNELS, THEREFORE, USEFUL IN THE TREATMENT OF ISCHEMIC STROKE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| CN-1226803-A | Diphenyl heterocycles as potassium channel modulators | BRISTOL MYERS SQUIBB CO (US) | 1999-08-25 | — | — | CN | disclosed |
| EP-0915856-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Bristol-Myers Squibb Company (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5869509-A | TREAT DISORDERS RESPONSIVE TO OPENERS OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998004135-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | SMN1; SMN2 494/4885TSHR 2352/4885SIGMAR1 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.